LABEXA
Acquired by
CERBA HEALTHCARE
LABEXA acquired by CERBA HEALTHCARE
Target
LABEXA
Acquirer
CERBA HEALTHCARE
Context
Cerba HealthCare acquired Labexa following a competitive auction process managed by Oddo BHF, beating out its main rival Biogroup. The acquisition allows Cerba to significantly strengthen its footprint in the French "Nouvelle-Aquitaine" region. The transaction followed Cerba's massive EUR1.2 billion acquisition of Lifebrain in Italy and was finalized shortly after Cerba's own LBO with EQT. The target's biologist-partners opted for an industrial exit to join a major laboratory network.
LABEXA, which reported an EBITDA margin of LOGIN in 2020, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN premium to the 12.8x average currently observed in the Healthcare & Pharma sector.
Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.
-> Deep-dive in Healthcare & Pharma market trends
Target
Labexa is a leading medical biology group in the Nouvelle-Aquitaine region, formed through the successive merger of several networks (Exalab, LBA, Sealab, and Accolab Sud-Ouest). It operates 94 sites with 1,000 employees across seven departments in southwestern France. In 2020, the group generated approximately EUR120 million in revenue.
Ent. Value
LOGIN
Equity Value
LOGIN
Multiples Analysis
EV / Revenue
LOGIN
EV / EBITDA
LOGIN
EV / EBIT
LOGIN
Historical Financials (EUR)
Other operations with LABEXA
mynth data is contributed by M&A / PE professionals and systematically cross-verified against private deal documents and official releases. All source materials are destroyed post-validation to guarantee data anonymity and compliance.